BioStock: CombiGene on the International Epilepsy Day and the pharmaceutical authorities' positive response
Yesterday was International Epilepsy Day which aims to put the spotlight on a devastating disease caused by overactive nerve cells in the brain. According to WHO, epilepsy affects about 50 million people worldwide, making it one of the most common neurological diseases globally. Approximately 30 percent of patients are not helped by existing drugs. BioStock reached out to Jan Nilsson, CEO of the gene therapy company CombiGene, who next year is planning to begin studies in humans with the genetherapy candidate CG01.
Read the full interview with Jan Nilsson at biostock.se:
This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/